Biotechnology
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
* Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY * Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion * Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI ,April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 60...
2026-04-27 17:03
4310
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...
2026-04-26 19:00
4565
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...
2026-04-24 21:00
2720
Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...
2026-04-24 20:00
3241
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...
2026-04-24 19:30
2637
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...
2026-04-24 19:03
2813
CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair
Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...
2026-04-24 14:58
2833
Servier completes the acquisition of Day One Biopharmaceuticals
* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs. * Transaction represents total equity ...
2026-04-23 20:30
3604
Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing "China Solution" and Winning Three Major Awards
JAKARTA, Indonesia, April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth Asia-Pacific Awards 2026 at the Grand Hyatt Jakarta, joining a distinguished community of healthcare...
2026-04-23 16:46
3499
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...
2026-04-23 16:22
4496
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026-04-23 15:02
1255
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...
2026-04-23 15:00
3304
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug P...
2026-04-23 14:14
3038
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in...
2026-04-23 11:37
2619
BioEngine Launches UltraFeed CHO Supplement, Boosting Titers by Up to 48%
SHANGHAI, April 23, 2026 /PRNewswire/ -- Shanghai BioEngine Sci-tech Co., Ltd. announced the launch of UltraFeed, a next-generation fed-batch supplement designed to elevate CHO cell productivity in monoclonal antibody, bispecific, and recombinant protein manufacturing. Across diverse cell lines a...
2026-04-23 09:17
2919
Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...
2026-04-23 06:30
3970
GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists
PISCATAWAY, N.J., April 23, 2026 /PRNewswire/ -- GenScript Biotech Corporation
2026-04-23 04:03
1892
Samsung Biologics Reports First Quarter 2026 Financial Results
* Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion * Performance driven by full utilization across Plants 1 through 4 and robust operational execution * Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEO...
2026-04-22 14:50
3499
AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore
SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a c...
2026-04-22 14:13
3539
Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...
2026-04-22 11:09
2612
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 305 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 302 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 289 media titles]
2026-05-18 15:30
AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
7666
